Phase I–II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors
OBI-888 was well tolerated. Prolonged SD was noted in three patients. ADCC was induced after each OBI-888 treatment.
Authors
- Darren Sigal (ORCID: https://orcid.org/0000-0001-7839-1230)
- Li‐Yuan Bai (ORCID: https://orcid.org/0000-0001-7739-4077)
- Howard S. Höchster (ORCID: https://orcid.org/0000-0002-9893-1529)
- Yee Chao (ORCID: https://orcid.org/0000-0001-5578-340X)
- Apostolia Maria Tsimberidou (ORCID: https://orcid.org/0000-0003-2713-233X)
- Axel Grothey (ORCID: https://orcid.org/0000-0002-9341-6499)
- Heinz-Josef Lenz
- M. Wayne Saville
- Chia-Jui L Yen
- Dong Xu
Institutions
- Rutgers, The State University of New Jersey (US)
- The University of Texas MD Anderson Cancer Center (US)
- China Medical University (TW)
- Taipei Veterans General Hospital (TW)
- West Cancer Center (US)
- MEI Pharma (United States) (US)
- USC Norris Comprehensive Cancer Center (US)
- China Medical University Hospital (TW)
- Scripps Clinic (US)
- National Cheng Kung University Hospital (TW)
- Rutgers Cancer Institute (US)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1007/s00280-024-04714-z
- Citations
- 2
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Cancer Institute